Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial

BACKGROUND: In the phase 3 SOLO2 trial (ENGOT Ov-21), maintenance therapy with olaparib tablets significantly prolonged progression-free survival (primary endpoint) compared with placebo in patients with a germline BRCA1 or BRCA2 (BRCA1/2) mutation and platinum-sensitive, relapsed ovarian cancer who...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Lancet Oncol
Hlavní autoři: Friedlander, Michael, Gebski, Val, Gibbs, Emma, Davies, Lucy, Bloomfield, Ralph, Hilpert, Felix, Wenzel, Lari B, Eek, Daniel, Rodrigues, Manuel, Clamp, Andrew, Penson, Richard T, Provencher, Diane, Korach, Jacob, Huzarski, Tomasz, Vidal, Laura, Salutari, Vanda, Scott, Clare, Nicoletto, Maria Ornella, Tamura, Kenji, Espinoza, David, Joly, Florence, Pujade-Lauraine, Eric
Médium: Artigo
Jazyk:Inglês
Vydáno: 2018
Témata:
Article
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7869962/
https://ncbi.nlm.nih.gov/pubmed/30026002
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S1470-2045(18)30343-7
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky